Evaluation of direct medical and non-medical costs of Unfractionated Heparin and Low Molecular Weight Heparin in Hospitalized Patients with Stroke due to Atrial Fibrillation

Diagnosis and treatment of patients with stroke spent high expenses annually. The aim of this study is to evaluate the direct medical and non-medical costs of stroke patients of Nemazee hospital.
This study is a descriptive, cross-sectional analysis that from April to July 2015 Namazi Hospital in Shiraz. The study population in this studies all patients with stroke in atrial fibrillation patients who have been treated with drugs or heparin clexan. The sample size was 80 and data were collected by questionnaire form and through interview. sampling was stratified sampling. Data were analyzed with using SPSS 18 software and descriptive statistics, t-test and one-way ANOVA test.
Average direct medical costs, direct non-medical costsand indirects costs of unfractionated heparinwere: 27,340,000±10,010,000 Rials, 3,862,750 ± 2,851,490 Rials and 5,382,500 ± 4,934,950 Rials respectively. Same averagedirect medical costs, direct non-medical costsand indirects costs of low molecular weight heparin were: 24,664,250±14,649,890 Rials, 2,233,500±4,249,590 Rials and 2,572,500±2,625,310 Rials respectively.
Clexane drug compared to heparin treatment option with less total cost on the prevention of stroke in patients. The results of this study can also help patients to specialists and neurologists who can clexane of drug use in the treatment of lower cost.